ClinicalTrials.gg
Not yet recruitingNCT06228391Updated Jan 29, 2024

Ketamine Treatment for PTSD and MDD in TBI

A Phase 2 interventional study of IV ketamine and Midazolam in PTSD, Post Traumatic Stress Disorder, Major Depressive Disorder and Traumatic Brain Injury, sponsored by Minneapolis Veterans Affairs Medical Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-29.

Sponsored by Minneapolis Veterans Affairs Medical Center · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 114 studies in Combat Disorders with a site in United States — 41 open to participants now, 44 under way, 2 of them phase 3. Combat Disorders · United States.

Planned enrollment
61st of 100
40 · median 74
Started
2024
with 2 others
Phase 2
10 of 114
5 open now
Primary completion
2026-12
later than 7 of 43 live
Registered
63rd of 114
by date

Among the 114 studies in Combat Disorders with a site in United States, this one is the 61st largest by planned enrollment of the 100 interventional ones that give a count, is one of 3 that started in 2024, is one of 10 in phase 2, reaches primary completion later than 7 of the 43 other live ones, and was the 63rd registered.

Combat Disorders

204 studies on the registry are indexed under Combat Disorders; 93 are open to participants now.

Browse Combat Disorders studies →

Open to participants now

41 of the 114 studies in Combat Disorders with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 53 Combat Disorders studies recruiting now, 22 (42%) set no upper age limit and 26 (49%) stop at 75 or younger; 10 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Combat Disorders with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to examine the use of sedative ketamine to treat depression and post-traumatic stress disorder (PTSD) in Veterans with mild to moderate traumatic brain injury (TBI). The main questions it aims to answer are:

  • Efficacy of ketamine to reduce symptoms of depression and/or PTSD
  • Safety of ketamine to treat depression and/or PTSD in TBI Participants will be randomly assigned to receive either ketamine or midazolam (active placebo) twice a week for 3 weeks. During participation, subjects will be interviewed, have lab tests, and complete rating scales, and questionnaires.
03

Conditions studied

  • PTSD, Post Traumatic Stress Disorder
  • Major Depressive Disorder
  • Traumatic Brain Injury

Keywords

  • Veteran
  • Ketamine
  • PTSD
  • Depression
  • TBI
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willingness/able to sign .
  • Able to read and write in English.
  • Male or female Veterans aged 18-55 years old.
  • Remote history of TBI mild-moderate that is ≥12 weeks post-injury (chronic period) that met at minimum the 2021 VA/DoD Clinical Practice Guideline for the Management and Rehabilitation of Post-Acute Mild Traumatic Brain Injury (i.e., new onset or worsening of at least one of the following clinical signs immediately following the event: loss or decreased of consciousness, period of posttraumatic amnesia, period of being dazed and confused, and neurologic deficits).
  • Lifetime history of treatment resistance to at least one adequate trial of an antidepressant as determined by the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (MGH-ATRQ).
  • FDA-approved antidepressant, trazodone, atypical neuroleptic, prazosin, or clonidine with stable treatment, as determined by the study clinician, for at least 4 weeks prior to randomization. Following randomization, changes to doses may be allowable at the investigator's discretion

Exclusion criteria

Exclusion Criteria:

  • Ketamine treatment within the last 6 months

    • Lifetime history of psychosis-related disorder, current episode of mania/hypomania/mixed assessed by the Mini-International Neuropsychiatric Interview (MINI 7.0 for ).
    • History of penetrating head wounds or severe traumatic brain injury (Glasgow Coma Scale \<9; loss of consciousness >24hr; post-traumatic amnesia>7 days).
    • Severe substance and/or alcohol use disorder (DSM-5-TR) within six months of initial assessment; presence of illicit drugs (except cannabis) by positive urine toxicology at screening.
    • Intellectual disability or pervasive developmental disorder; dementia of any type.
    • Any disorder that, based on the Principal Investigator\'s judgement, would increase risk (e.g., unstable cardiac conditions) or protocol adherence (e.g., severe personality disorder).
    • For women: pregnancy (confirmed by lab test), initiation of female hormonal treatments within 3 months of screening, or inability/ unwillingness to use a medically accepted method during the study. Women who are surgically sterile or have been for at least 1 year will not be excluded
    • At screening, resting blood pressure (sitting or supine) lower than 90/60 or higher than 150/90, or resting heart rate lower than 45/min or higher than 100/min.
    • Imminent risk of suicidal/homicidal ideation and/or behavior with intent and/or plan.
    • Concurrent participation in a cognitive rehabilitation program, however patient will have a TBI clinician involved in directed services.
    • Subjects on a prohibited medication: monoamine oxidase inhibitors, memantine, long acting benzodiazepines (i.e., Chlordiazepoxide, Diazepam, Flurazepam)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Ketamine

    Twice a week ketamine IV 0.5 mg/kg

    Drug: IV ketamine

  • Active comparator
    Midazolam

    Twice a week midazolam IV 0.045 mg/kg

    Drug: Midazolam

Interventions

  • DrugKetamineStudies of KetamineKetamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will receive a single infusion of racemic ketamine at 0.5mg/kg for 40 minutes twice a week for 3 weeks.

  • Subjects will receive a single infusion of midazolam at 0.045mg/kg for 40 minutes twice a week for 3 weeks.

06

What researchers measure

Primary outcomes

  1. Change in Severity of Depressive Symptoms

    Total score on the Montgomery- Åsberg Depression Rating Scale , a semi- structured 10-item scale. Range 0-60. Higher values represent worse outcomes. The total score is obtained by summing the severity score of each item.

    Time frame: 3 weeks

Secondary outcomes

  1. Change in Severity of Post-traumatic Stress Disorder (PTSD) Symptoms

    Total score on the PTSD Checklist for DSM-5 (PCL-5), a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD. The total score is obtained by summing the score of each item.

    Time frame: 3 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2024; primary completion for Dec 2026, 33 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2024
First posted
Jan 29, 2024
StartEst.
Mar 2024
Primary completionEst.
Dec 2026
CompletionEst.
Mar 2027
Last update
Jan 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06228391
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Responsible party
Paulo Shiroma (Psychiatrist, Minneapolis Veterans Affairs Medical Center) — Principal investigator
First posted
Jan 29, 2024
Start date
Mar 2024 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jan 29, 2024

Study contacts

Paulo Shiroma, MD
Contact
paulo.shiroma@va.gov
612-467-2264
Seth Dsiner, PhD
Contact
seth.disner@va.gov
612-629-7349

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion